![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (53)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Erin
E. Morgan, Steven
Paul Woods, Alexandra Rooney, William Perry, Igor Grant, Scott
L. Letendre & the HIV Neurobehavioral Research Program (HNRP) Group. (2012) Intra-Individual Variability Across Neurocognitive Domains in Chronic Hepatitis C Infection: Elevated Dispersion is Associated With Serostatus and Unemployment Risk. The Clinical Neuropsychologist 26:4, pages 654-674.
Read now
Read now
Felicia C Allen-Ramey, Shaloo Gupta & Marco daCosta DiBonaventura. (2012) Patient characteristics, treatment patterns, and health outcomes among COPD phenotypes. International Journal of Chronic Obstructive Pulmonary Disease 7, pages 779-787.
Read now
Read now
Marco daCosta DiBonaventura, Ryne Paulose-Ram, Jun Su, Margaret McDonald, Kelly H. Zou, Jan-Samuel Wagner & Hemal Shah. (2012) The Impact of COPD on Quality of Life, Productivity Loss, and Resource Use among the Elderly United States Workforce. COPD: Journal of Chronic Obstructive Pulmonary Disease 9:1, pages 46-57.
Read now
Read now
Articles from other publishers (50)
Valérie Hervieux, Caroline Biron & Justine Dima. (2023) Investigating Associations Between Physical Activity and Presenteeism – A Scoping Review. American Journal of Health Promotion 37:8, pages 1147-1161.
Crossref
Crossref
Misbah Nosheen & Sajjad Khan. (2022) The Economic Burden of Viral hepatitis C infection at various stages of the disease in District Mardan, Pakistan. Pakistan BioMedical Journal, pages 226-230.
Crossref
Crossref
Dr Nick Scott, Ms Anna Palmer, Mr Tom Tidhar, Prof Mark Stoove, Dr Rachel Sacks-Davis, A/Prof Joseph S. Doyle, Dr Alisa Pedrana, Prof Alexander J. Thompson, Prof David P. Wilson & Prof Margaret Hellard. (2022) Assessment of the cost-effectiveness of Australia's risk-sharing agreement for direct-acting antiviral treatments for hepatitis C: a modelling study. The Lancet Regional Health - Western Pacific 18, pages 100316.
Crossref
Crossref
Aaron G. Lim, Nick Scott, Josephine G. Walker, Saeed Hamid, Margaret Hellard & Peter Vickerman. (2021) Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLOS Medicine 18:10, pages e1003818.
Crossref
Crossref
Nick Scott, Thin Mar Win, Tom Tidhar, Hla Htay, Bridget Draper, Phyo Thu Zar Aung, Yinzong Xiao, Anna Bowring, Christian Kuschel, Sonjelle Shilton, Khin Pyone Kyi, Win Naing, Khin Sanda Aung & Margaret Hellard. (2021) Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. The Lancet Regional Health - Western Pacific 10, pages 100129.
Crossref
Crossref
Alessio Aghemo, Alfredo Alberti, Pietro Andreone, Mario Angelico, Maurizia Rossana Brunetto, Luchino Chessa, Alessia Ciancio, Antonio Craxì, Giovanni Battista Gaeta, Massimo Galli, Antonio Gasbarrini, Alessia Giorgini, Elisabetta Grilli, Pietro Lampertico, Miriam Lichtner, Michele Milella, Filomena Morisco, Marcello Persico, Mario Pirisi, Massimo Puoti, Giovanni Raimondo, Antonietta Romano, Maurizio Russello, Vincenzo Sangiovanni, Monica Schiavini, Gaetano Serviddio, Erica Villa, Maria Vinci, Antonella De Michina, Valentina Gallinaro, Giuliana Gualberti, Antonio Saverio Roscini & Anna Linda Zignego. (2021) Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. Digestive and Liver Disease 53:5, pages 612-619.
Crossref
Crossref
Kieu‐Dung Nguyen, Van‐AnhThi Tran & Duc‐Thanh Nguyen. (2020) Social insurance reform and absenteeism in Vietnam. International Journal of Social Welfare 30:2, pages 193-207.
Crossref
Crossref
Zobair M. Younossi & Linda Henry. 2021. Hepatitis C: Care and Treatment. Hepatitis C: Care and Treatment
213
219
.
Alisa Pedrana, Jessica Howell, Nick Scott, Sophia Schroeder, Christian Kuschel, Jeffrey V Lazarus, Rifat Atun, Ricardo Baptista-Leite, Ellen 't Hoen, Sharon J Hutchinson, Lisa Aufegger, Raquel Peck, Annette H Sohn, Tracy Swan, Mark Thursz, Olufunmilayo Lesi, Manik Sharma, John Thwaites, David P Wilson & Margaret Hellard. (2020) Global hepatitis C elimination: an investment framework. The Lancet Gastroenterology & Hepatology 5:10, pages 927-939.
Crossref
Crossref
Nick Scott, Christian Kuschel, Alisa Pedrana, Sophia Schroeder, Jessica Howell, Alexander Thompson, David P Wilson & Margaret Hellard. (2020) A model of the economic benefits of global hepatitis C elimination: an investment case. The Lancet Gastroenterology & Hepatology 5:10, pages 940-947.
Crossref
Crossref
Sophia E. Schröeder, Alisa Pedrana, Nick Scott, David Wilson, Christian Kuschel, Lisa Aufegger, Rifat Atun, Ricardo Baptista‐Leite, Maia Butsashvili, Manal El‐Sayed, Aneley Getahun, Saeed Hamid, Radi Hammad, Ellen ‘t Hoen, Sharon J. Hutchinson, Jeffrey V. Lazarus, Olufunmilayo Lesi, Wangsheng Li, Rosmawati Binti Mohamed, Sigurdur Olafsson, Raquel Peck, Annette H. Sohn, Mark Sonderup, Catherine W. Spearman, Tracy Swan, Mark Thursz, Tim Walker, Margaret Hellard & Jessica Howell. (2019) Innovative strategies for the elimination of viral hepatitis at a national level: A country case series. Liver International 39:10, pages 1818-1836.
Crossref
Crossref
Zobair M. Younossi, Maria Stepanova, Issah Younossi, George Papatheodoridis, Harry L.A. Janssen, Kosh Agarwal, Mindie H. Nguyen, Ed Gane, Naoky Tsai & Fatema Nader. (2019) Patient‐reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication. Liver International 39:10, pages 1837-1844.
Crossref
Crossref
Josep Mallolas, Adriana Ahumada, Javier Ampuero, José Ramón Blanco, Álvaro Hidalgo, Maria-Carlota Londoño, Esther Molina & Salvador Ruiz. (2019) Calidad de vida en los pacientes con hepatitis C. Importancia del tratamiento. Gastroenterología y Hepatología 42, pages 20-25.
Crossref
Crossref
Zobair M. Younossi, Pegah Golabi & Linda Henry. (2019) A Comprehensive Review of Patient-reported Outcomes in Patients With Chronic Liver Diseases. Journal of Clinical Gastroenterology 53:5, pages 331-341.
Crossref
Crossref
Adauto CASTELO, Carlos Eduardo BRANDÃO MELLO, Rosangela TEIXEIRA, Jose Valdez Ramalho MADRUGA, Tania REUTER, Leila Maria Moreira Beltrão PEREIRA, Giovanni Faria SILVA, Mario Reis ÁLVARES-DA-SILVA, Heverton ZAMBRINI & Paulo Roberto Abrão FERREIRA. (2018) HEPATITIS C IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM: BURDEN OF DISEASE. Arquivos de Gastroenterologia 55:4, pages 329-337.
Crossref
Crossref
Zobair M. Younossi, Maria Stepanova, Linda Henry, Kwang-Hyub Han, Sang Hoon Ahn, Young-Suk Lim, Wan-Long Chuang, Jia-Horng Kao, Kinh V. Nguyen, Ching Lung Lai, Henry Lik-Yuen Chan & Lai Wei. (2018) Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. Journal of Viral Hepatitis 25:12, pages 1429-1437.
Crossref
Crossref
Fabiane Mateus Siqueira, Vinicius Lins Ferreira, Helena Hiemisch Lobo Borba & Roberto Pontarolo. (2018) Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies. Revista do Instituto de Medicina Tropical de São Paulo 60:0.
Crossref
Crossref
Zobair Younossi, Georgios Papatheodoridis, Patrice Cacoub, Francesco Negro, Heiner Wedemeyer, Linda HenryAngelos Hatzakis. (2018) The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease. Journal of Viral Hepatitis 25, pages 6-14.
Crossref
Crossref
Patricia A. M. Kracht, Faydra I. Lieveld, Linde M. Amelung, Carina J. R. Verstraete, Eveline P. Mauser-Bunschoten, Joep de Bruijne, Peter D. Siersema, Andy I. M. Hoepelman, Joop E. Arends & Karel J. van Erpecum. (2018) The Impact of Hepatitis C Virus Direct-Acting Antivirals on Patient-Reported Outcomes: A Dutch Prospective Cohort Study. Infectious Diseases and Therapy 7:3, pages 373-385.
Crossref
Crossref
Sammy Saab, Darshan Mehta, Stacie Hudgens, Nathan Grunow, Yanjun Bao & Brett Pinsky. (2018) Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C. Liver International 38:8, pages 1377-1394.
Crossref
Crossref
Lucas Pereira Jorge de Medeiros, Mario Barreto Correa Lima, Marcia Maria Amêndola Pires, Alessandra Mendonça Almeida Maciel, Renata Barboza Vianna Medeiros, Mariana Dermínio Donadel, Isabela Martins Becattini Pereira, Fábio Marchon Leão, Luiz Eduardo Amorim Correa Lima Pires, Helio Rzetelna & Carlos Eduardo Brandão-Mello. (2018) Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C. Osong Public Health and Research Perspectives 9:2, pages 50-58.
Crossref
Crossref
Giulia Malaguarnera, Gaetano Bertino, Carmela Greco, Caterina Gagliano, Massimo Motta, Giuseppe Chisari, Venerando Rapisarda, Giuseppe Nunnari, Michele Vecchio, Filippo Drago & Michele Malaguarnera. (2017) Job performance in chronic hepatitis C virus patients treated with pegylated interferon-α2b plus ribavirin: an observational study. Translational Medicine Communications 2:1.
Crossref
Crossref
Milan Milošević, Jelena Jakab, Lucija Kuna & Martina Smolić. 2017. Update on Hepatitis C. Update on Hepatitis C.
Do Young Kim, Kwang-Hyub Han, Byungyool Jun, Tae Hyun Kim, Sohee Park, Thomas Ward, Samantha Webster & Phil McEwan. (2017) Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLOS ONE 12:1, pages e0167770.
Crossref
Crossref
Zobair M. Younossi, Aybike Birerdinc & Linda Henry. (2016) Hepatitis C infection: A multi-faceted systemic disease with clinical, patient reported and economic consequences. Journal of Hepatology 65:1, pages S109-S119.
Crossref
Crossref
Z. M. Younossi, M. Stepanova, L. Henry, I. Younossi, A. Weinstein, F. Nader & S. Hunt. (2016) Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. Journal of Viral Hepatitis 23:8, pages 623-630.
Crossref
Crossref
Zobair M Younossi, Maria Stepanova, Linda Henry, Fatema Nader & Sharon Hunt. (2016) An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens. American Journal of Gastroenterology 111:6, pages 808-816.
Crossref
Crossref
S. Gupta & Z. Wang. (2016) Treatment satisfaction with different weight loss methods among respondents with obesity. Clinical Obesity 6:2, pages 161-170.
Crossref
Crossref
Ellen J. Huisman, Suzanne van Meer, Bart van Hoek, Hanneke van Soest, Karin M.J. van Nieuwkerk, Joop E. Arends, Peter D. Siersema & Karel J. van Erpecum. (2016) Effects of preventive versus “on-demand” nutritional support on paid labour productivity, physical exercise and performance status during PEG-interferon-containing treatment for hepatitis C. Clinics and Research in Hepatology and Gastroenterology 40:2, pages 221-229.
Crossref
Crossref
Z. Younossi, A. Brown, M. Buti, S. Fagiuoli, S. Mauss, W. Rosenberg, L. Serfaty, A. Srivastava, N. Smith, M. Stepanova & R. Beckerman. (2016) Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. Journal of Viral Hepatitis 23:3, pages 217-226.
Crossref
Crossref
Issah Younossi, Ali Weinstein, Maria Stepanova, Sharon Hunt & Zobair M. Younossi. (2016) Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity. Psychosomatics 57:1, pages 82-88.
Crossref
Crossref
Brian W. Ward. (2015) Multiple chronic conditions and labor force outcomes: A population study of U.S. adults. American Journal of Industrial Medicine 58:9, pages 943-954.
Crossref
Crossref
J. Scott, L. Gilles, M. Fu, E. Brohan, C. Panter, R. Arbuckle, W. Jessner & M. Beumont. (2014)
Simeprevir added to peginterferon and ribavirin lessens time with fatigue, depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the
QUEST
‐1,
QUEST
‐2 and
PROMISE
studies
. Journal of Viral Hepatitis 22:8, pages 639-650.
Crossref
Crossref
Zobair M. Younossi, Maria Stepanova, Nezam Afdhal, Kris V. Kowdley, Stefan Zeuzem, Linda Henry, Sharon L. Hunt & Patrick Marcellin. (2015) Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. Journal of Hepatology 63:2, pages 337-345.
Crossref
Crossref
J. Yu, S. Wang & X. Yu. (2015) Health risk factors associated with presenteeism in a Chinese enterprise. Occupational Medicine, pages kqv115.
Crossref
Crossref
Jennifer C. Samp, Richard Perry, James Piercy, Robert Wood & Robert W. Baran. (2015) Patient health utility, work productivity, and lifestyle impairment in chronic hepatitis C patients in France. Clinics and Research in Hepatology and Gastroenterology 39:3, pages 307-314.
Crossref
Crossref
Zobair M. Younossi, Yushan Jiang, Nathaniel J. Smith, Maria Stepanova & Rachel Beckerman. (2015) Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology 61:5, pages 1471-1478.
Crossref
Crossref
Z. Younossi & L. Henry. (2015) Systematic review: patient-reported outcomes in chronic hepatitis C - the impact of liver disease and new treatment regimens. Alimentary Pharmacology & Therapeutics 41:6, pages 497-520.
Crossref
Crossref
J. Aggarwal, M. Vera-Llonch, M. Donepudi, E. Suthoff, Z. Younossi & T. F. Goss. (2015) Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. Journal of Viral Hepatitis 22:1, pages 8-17.
Crossref
Crossref
Zobair Younossi & Linda Henry. (2014) The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Digestive and Liver Disease 46, pages S186-S196.
Crossref
Crossref
Vignan Manne, Kareem Sassi, Ruby Allen & Sammy Saab. (2014) Hepatitis C and Work Impairment. Journal of Clinical Gastroenterology 48:7, pages 595-599.
Crossref
Crossref
A. Goren, K. H. Zou, S. Gupta & C. Chen. (2014) Direct and indirect cost of urge urinary incontinence with and without pharmacotherapy. International Journal of Clinical Practice 68:3, pages 336-348.
Crossref
Crossref
Marco daCosta DiBonaventura, Yong Yuan, Benedicte Lescrauwaet, Gilbert L’Italien, Gordon G. Liu, Isao Kamae & Josephine A. Mauskopf. (2014) Multicountry Burden of Chronic Hepatitis C Viral Infection among Those Aware of Their Diagnosis: A Patient Survey. PLoS ONE 9:1, pages e86070.
Crossref
Crossref
Shaloo Gupta, Amir Goren, Amy L Phillips, Fernando Dangond & Michelle Stewart. (2014) Self-reported severity among patients with multiple sclerosis in the U.S. and its association with health outcomes. Multiple Sclerosis and Related Disorders 3:1, pages 78-88.
Crossref
Crossref
Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford A Brass, Antoine C El Khoury, Fred Poordad, Jean-Pierre Bronowicki & Elamin H Elbasha. (2013) Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infectious Diseases 13:1.
Crossref
Crossref
Jeffrey Vietri, Girish Prajapati & Antoine C El Khoury. (2013) The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterology 13:1.
Crossref
Crossref
M. Michele Manos, Chanda K. Ho, Rosemary C. Murphy & Valentina A. Shvachko. (2013) Physical, Social, and Psychological Consequences of Treatment for Hepatitis C. The Patient - Patient-Centered Outcomes Research 6:1, pages 23-34.
Crossref
Crossref
Antoine C. El Khoury, Jeffrey Vietri & Girish Prajapati. (2012) The Burden of Untreated Hepatitis C Virus Infection: A US Patients’ Perspective. Digestive Diseases and Sciences 57:11, pages 2995-3003.
Crossref
Crossref
I. A. Rowe, D. D. Houlihan & D. J. Mutimer. (2012) Despite poor interferon response in advanced hepatitis C virus infection, models of protease inhibitor treatment predict maximum treatment benefit. Alimentary Pharmacology & Therapeutics 36:7, pages 670-679.
Crossref
Crossref
Marco daCosta DiBonaventura, Yong Yuan, Jan-Samuel Wagner, Gilbert J. L’Italien, Benedicte Lescrauwaet & Paul Langley. (2012) The burden of viral hepatitis C in Europe. European Journal of Gastroenterology & Hepatology 24:8, pages 869-877.
Crossref
Crossref